THERAPY DOSSIER · th-734f06f60445

VPC01091, a sphingosine-1-phosphate receptor 3 antagonist

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Fracture
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29983824 ↗2018Reported benefit

Novel Lipid Signaling Mediators for Mesenchymal Stem Cell Mobilization during Bone Repair.

MixedFractureCalvarial/defectAcute mobilisation of mesenchymal stem cells detected as early as 1.5 h after t…

Model: Critically sized rat cranial (calvarial) defect and bone morphogenetic protein-2 induced ectopic bone formation

VPC01091 mobilised mesenchymal stem cells into blood within 1.5 h, increased bone morphogenetic protein-2 induced ectopic bone and significantly increased new bone formation in critically sized rat cranial defects without impeding engraftment of transplanted mesenchymal stem cells.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…